S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
Log in

NASDAQ:ATRS - Antares Pharma Stock Price, Forecast & News

$2.08
-0.01 (-0.48 %)
(As of 04/2/2020 04:00 PM ET)
Today's Range
$2.02
Now: $2.08
$2.15
50-Day Range
$1.75
MA: $2.89
$3.70
52-Week Range
$1.60
Now: $2.08
$5.13
Volume616,621 shs
Average Volume1.68 million shs
Market Capitalization$344.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Read More
Antares Pharma logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$123.86 million
Cash Flow$0.00 per share
Book Value$0.33 per share

Profitability

Net Income$-2,030,000.00

Miscellaneous

Employees165
Market Cap$344.36 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.


Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

How has Antares Pharma's stock been impacted by COVID-19 (Coronavirus)?

Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATRS stock has decreased by 30.7% and is now trading at $2.08. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Antares Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Strong Buy." View analyst ratings for Antares Pharma.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Antares Pharma.

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) released its quarterly earnings data on Tuesday, March, 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.00 by $0.03. The specialty pharmaceutical company earned $37.84 million during the quarter, compared to the consensus estimate of $34.35 million. Antares Pharma had a negative net margin of 1.64% and a negative return on equity of 4.43%. View Antares Pharma's earnings history.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, March, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $147.56 million.

What price target have analysts set for ATRS?

2 equities research analysts have issued 1-year target prices for Antares Pharma's shares. Their forecasts range from $5.00 to $6.00. On average, they expect Antares Pharma's stock price to reach $5.50 in the next year. This suggests a possible upside of 164.4% from the stock's current price. View analysts' price targets for Antares Pharma.

Has Antares Pharma been receiving favorable news coverage?

News headlines about ATRS stock have been trending very negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Antares Pharma earned a news impact score of -3.3 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAntares Pharma.

Are investors shorting Antares Pharma?

Antares Pharma saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 4,735,600 shares, a decrease of 24.2% from the February 27th total of 6,250,000 shares. Based on an average daily trading volume, of 2,144,500 shares, the short-interest ratio is presently 2.2 days. Approximately 3.1% of the company's stock are short sold. View Antares Pharma's Current Options Chain.

Who are some of Antares Pharma's key competitors?

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Novavax (NVAX), Conatus Pharmaceuticals (CNAT), NVIDIA (NVDA), Advanced Micro Devices (AMD), Prospect Capital (PSEC), Hi-Crush Partners (HCLP), Macquarie Infrastructure (MIC), Amarin (AMRN) and AT&T (T).

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
  • Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $2.08.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $344.36 million and generates $123.86 million in revenue each year. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Antares Pharma employs 165 workers across the globe. View additional information about Antares Pharma.

What is Antares Pharma's official website?

The official website for Antares Pharma is http://www.antarespharma.com/.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]


MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  382 (Vote Outperform)
Underperform Votes:  302 (Vote Underperform)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel